P-040

P-040 is an investigational drug candidate being developed by Pangea Pharmaceuticals for the treatment of hypertension and angina. Pangea Pharmaceuticals is a specialty pharmaceutical company that focuses on the development of 'Value-Added Medicines,' which typically involve the reformulation, repurposing, or creation of new dosage forms of established active pharmaceutical ingredients (APIs) to improve clinical outcomes such as efficacy, safety, or patient adherence. While the specific active ingredient and molecular mechanism of P-040 have not been publicly disclosed by the developer, its dual indication for hypertension and angina is characteristic of cardiovascular agents such as calcium channel blockers or beta-adrenergic antagonists. The product is currently part of Pangea's development pipeline with an estimated launch target of 2025.